LLY

748.91

+3.51%↑

JNJ

177.53

-0.28%↓

ABBV

209.92

+0.22%↑

UNH

333.08

+5.11%↑

NVO

53.23

-2.19%↓

LLY

748.91

+3.51%↑

JNJ

177.53

-0.28%↓

ABBV

209.92

+0.22%↑

UNH

333.08

+5.11%↑

NVO

53.23

-2.19%↓

LLY

748.91

+3.51%↑

JNJ

177.53

-0.28%↓

ABBV

209.92

+0.22%↑

UNH

333.08

+5.11%↑

NVO

53.23

-2.19%↓

LLY

748.91

+3.51%↑

JNJ

177.53

-0.28%↓

ABBV

209.92

+0.22%↑

UNH

333.08

+5.11%↑

NVO

53.23

-2.19%↓

LLY

748.91

+3.51%↑

JNJ

177.53

-0.28%↓

ABBV

209.92

+0.22%↑

UNH

333.08

+5.11%↑

NVO

53.23

-2.19%↓

Начало・Списък с акции・Arbutus Biopharma Corp

Arbutus Biopharma Corp

Отворен

4.04 -2.65

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

Максимум

4.17

Ключови измерители
By Trading Economics
Приходи	27M 2.5M
Продажби	9M 11M
Марж на печалбата	23.494
Служители	44
EBITDA	27M 2.6M

Пазарни показатели
By TradingEconomics
Пазарна капитализация	72M 711M
Предишно отваряне	6.69
Предишно затваряне	4.04

Техническа оценка

By Trading Central

Увереност

Weak Bearish Evidence

3.255 / 3.365 Подкрепа & съпротива

Arbutus Biopharma Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

8.09.2025 г., 23:59 ч. UTC

Придобивния, сливания и поглъщания

Anglo American Is in Talks to Buy Teck Resources, Bloomberg Says

8.09.2025 г., 22:02 ч. UTC

Значими двигатели на пазара

Microsoft Signs $17.4 Billion AI Deal With Nebius

8.09.2025 г., 17:01 ч. UTC

Значими двигатели на пазара

Eightco Holdings Stock Surges as Dan Ives Joins Board Amid Crypto Push

8.09.2025 г., 17:01 ч. UTC

Значими двигатели на пазара

Tron Shares Rise After New Investment From Bravemorning

8.09.2025 г., 16:14 ч. UTC

Значими двигатели на пазара

Beyond Air Shares Climb on FDA Orphan Drug Designation for Brain Cancer Treatment

8.09.2025 г., 16:13 ч. UTC

Значими двигатели на пазара

Dianthus Shares Whipsaw on Strong Trial Results, Safety Concerns

8.09.2025 г., 23:12 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

8.09.2025 г., 23:12 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

8.09.2025 г., 23:12 ч. UTC

Пазарно говорене

Infratil's New Bull Likes Exposure to Growing Infrastructure Businesses -- Market Talk

8.09.2025 г., 22:56 ч. UTC

Пазарно говорене

Worst May Be Over for New Zealand Retailers -- Market Talk

8.09.2025 г., 22:23 ч. UTC

Пазарно говорене

Ebos's Near-Term Earnings Outlook Dims -- Market Talk

8.09.2025 г., 21:51 ч. UTC

Пазарно говорене

AT&T Backs Outlook After EchoStar Spectrum Purchase -- Market Talk

8.09.2025 г., 21:47 ч. UTC

Значими двигатели на пазара

Microsoft Signs $17.4B AI Deal With Nebius

8.09.2025 г., 21:33 ч. UTC

Придобивния, сливания и поглъщания

This Quantum Pure Play Is Going Public. What Infleqtion Does Differently, Says Its CEO. -- Barrons.com

8.09.2025 г., 21:20 ч. UTC

Придобивния, сливания и поглъщания

MEG Energy Plans to Respond on or Before Sept 15 >MEG.T

8.09.2025 г., 21:19 ч. UTC

Придобивния, сливания и поглъщания

MEG Energy Special Committee and Board Will Evaluate Revised Strathcona Offer >MEG.T

8.09.2025 г., 21:18 ч. UTC

Придобивния, сливания и поглъщания

MEG Energy Acknowledges Strathcona's Intention to Revise Offer

8.09.2025 г., 20:50 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Tech, Media & Telecom Roundup: Market Talk

8.09.2025 г., 19:33 ч. UTC

Пазарно говорене

Oil Futures Gain Despite Planned OPEC+ Output Increases -- Market Talk

8.09.2025 г., 19:22 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Settle Higher -- Market Talk

8.09.2025 г., 19:02 ч. UTC

Пазарно говорене

Dollar Lukewarm Amid Data Hiatus Ahead of August CPI -- Market Talk

8.09.2025 г., 18:24 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

8.09.2025 г., 18:24 ч. UTC

Пазарно говорене

Weaker Argentine Peso Profitable for Grain Producers -- Market Talk

8.09.2025 г., 17:29 ч. UTC

Пазарно говорене

Mexican Inflation Seen Little Changed in August -- Market Talk

8.09.2025 г., 16:59 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

SpaceX Spectrum Acquisition Will Create More Satellite Connection Supply, Verizon CEO Says -- Market Talk

8.09.2025 г., 16:36 ч. UTC

Пазарно говорене

Crude Futures Hold Gains After OPEC+ Output Decision -- Market Talk

8.09.2025 г., 16:20 ч. UTC

Пазарно говорене

Tech, Media & Telecom Roundup: Market Talk

8.09.2025 г., 16:16 ч. UTC

Печалби

Strategy Stock May Not Ever Make It Into the S&P 500 Index -- Barrons.com

8.09.2025 г., 16:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

8.09.2025 г., 16:04 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

Сравнение с други в отрасъла

Ценова промяна

Arbutus Biopharma Corp Прогноза

Консенсусна оценка

By TipRanks

0 ratings

Купи

Задържане

Продай

Според 0 анализатори, дали борсови рейтинги на Arbutus Biopharma Corp през последните 3 месеца.

Техническа оценка

By Trading Central

3.255 / 3.365Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Arbutus Biopharma Corp

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.